Article Text

Download PDFPDF

PO.6.140 Treatment pattern of patients with systemic lupus erythematosus: a cohort study at rheumatologist practices in germany
  1. J Montonen1,
  2. S De Souza1,
  3. C Foch1,
  4. C Vazquez-Mateo2,
  5. S Roy3 and
  6. T Dörner4
  1. 1Global Epidemiology, Merck Healthcare KGaA ~ Darmstadt ~ Germany
  2. 2Global Clinical Development, EMD Serono Research and Development Institute, Inc., an affiliate of Merck KGaA ~ Billerica ~ USA
  3. 3Global Clinical Development, Ares Trading SA, an affiliate of Merck KGaA ~ Eysins ~ Switzerland
  4. 4Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin ~ Germany


Purpose Patients with lupus are chronically exposed to anti-inflammatory and immunosuppressive treatments that are associated with considerable morbidities. This study aimed to describe treatment patterns of systemic lupus erythematosus (SLE) patients in Germany.

Methods One cohort of SLE patients who were diagnosed between 2001 and 2019 and treated at primary care rheumatologist practices were selected in the German IQVIA Disease Analyzer. This database provides anonymized data on prescriptions directly from the participating practice’s computer systems. Patients were followed from the first recorded diagnosis until the earliest of their last visit or September 2020. Prescriptions were described with percentages calculated based on the number of patients with ≥1 visit during yearly time intervals.

Results A total of 423 SLE patients were included. The median (Q1, Q3) follow-up was 4.2 (1.6, 8.1) years. Median age was 50 years and 85% were female. Glucocorticoids (GCs) were the most prescribed treatments in the first 5 years following diagnosis with SLE (52–70% of patients prescribed oral GCs per year). Antimalarials and immunosuppressants were the second most prescribed treatments: antimalarials (32–39%), azathioprine (15–17%), methotrexate oral (7–10%) or subcutaneous (4–7%), and mycophenolate (5–7%). Biologics (e.g., belimumab, rituximab, tocilizumab) were prescribed for <4% of patients. Opioids were prescribed for 5–8% of patients. A trend towards decreased use of GCs was observed in SLE patients diagnosed between 2015 and 2019 versus patients diagnosed between 2001 and 2009 (47–64% vs 44–74%). Use of opioids also decreased (2–5% vs 6–13%). Biologics use remained limited (3–4% vs 0–5%).

Conclusions In primary care rheumatologist practices in Germany, GCs remain the cornerstone treatment for SLE although there is a trend of decreased usage, antimalarials are also widely used, as well as immunosuppressants. Biologic treatments are used infrequently. Pain management included use of opioids. The prescription patterns were similar to those observed in other German cohort studies (Albrecht et al. Lupus Sci Med. 2014;1:e000059 and 2021;8:e000526).

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.